Milestone Pharmaceuticals

Update in progress

MIST (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on cardiovascular medicines for the United States and Canada. Its lead product, CARDAMYST (etripamil) nasal spray, is prescribed to convert acute PSVT episodes to sinus rhythm in adults. The company also develops etripamil for AFib with rapid ventricular rate (AFib‑RVR). It has a licensing and collaboration agreement with Corxel Pharmaceuticals. Founded in 2003, it is headquartered in Montreal, Canada.

Company score

Sentiment: 0.37; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.28; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive